There are currently 25 clinical trials in Norman, Oklahoma looking for participants to engage in research studies. Trials are conducted at various facilities, including Central Sooner Research, Lynn Institute of Norman, Cancer Care Associates - Norman and Alliance for Multispecialty Research, LLC. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)
Recruiting
The main purpose of this study is to assess the dose-response relationship of maridebart cafraglutide on glucose control compared with placebo.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Alliance for Multispecialty Research, Norman, Oklahoma
Conditions: Type 2 Diabetes Mellitus (T2DM)
A Study to Assess the Efficacy and Safety of RO7790121 for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
Recruiting
This Phase III, multicenter, double-blind, placebo-controlled, treat-through study will evaluate the efficacy and safety of RO7790121 compared with placebo in participants with moderately to severely active ulcerative colitis (UC).
Gender:
ALL
Ages:
Between 16 years and 80 years
Trial Updated:
03/10/2025
Locations: Central Sooner Research, Norman, Oklahoma
Conditions: Moderately to Severely Active Ulcerative Colitis
A Study of CT-388 in Participants Who Are Overweight or Obese with Type 2 Diabetes Mellitus
Recruiting
This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of CT-388 at low, middle, and high doses in participants who are overweight or obese with Type 2 diabetes mellitus (T2DM).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/28/2025
Locations: Alliance for Multispecialty Research, LLC (AMR Norman), Norman, Oklahoma
Conditions: Overweight or Obese, Type 2 Diabetes Mellitus (T2DM)
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
Recruiting
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and inadequate glycemic control with metformin with or without sodium-glucose cotransporter-2 inhibitor (SGLT2i). The study will last about 26 months and may include up to 24 visits.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: Alliance for Multispecialty Research, LLC, Norman, Oklahoma
Conditions: Diabetes Mellitus, Type 2
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Recruiting
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.
Gender:
ALL
Ages:
45 years and above
Trial Updated:
02/27/2025
Locations: Alliance for Multispecialty Research, LLC, Norman, Oklahoma
Conditions: Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
Recruiting
This study will evaluate the efficacy and safety of Armour Thyroid treatment compared with synthetic T4 in subjects who have primary hypothyroidism and are currently stabilized (i.e., in-range thyroid-stimulating hormone \[TSH\]) on synthetic T4 treatment. This study will also therefore evaluate the efficacy and safety of dose conversion from synthetic T4 therapy to Armour Thyroid therapy.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/26/2025
Locations: Lynn Institute of Norman /ID# 256785, Norman, Oklahoma
Conditions: Hypothyroidism
Once-weekly Petrelintide Versus Placebo for Obesity or Overweight with Co-morbidities
Recruiting
The main purpose of this study is to compare dose levels of petrelintide versus placebo with regards to effect on body weight, safety, and tolerability.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2025
Locations: AMR Norman, Norman, Oklahoma
Conditions: Obesity
Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia
Recruiting
This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with hypertriglyceridemia (HTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo and be evaluated for efficacy and safety.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/17/2025
Locations: Lynn Institute of Norman, Norman, Oklahoma
Conditions: Hypertriglyceridemia
Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
Recruiting
This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with severe hypertriglyceridemia (SHTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo, and be evaluated for efficacy and safety. After month 12, eligible participants will be offered an opportunity to continue in an optional open-label extension under a separate protocol.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: Lynn Institute of Norman, Norman, Oklahoma
Conditions: Severe Hypertriglyceridemia
A Research Study to See How Much CagriSema (1.0 mg Once Weekly) Lowers Blood Sugar and Body Weight Compared to Tirzepatide (5 mg Once Weekly) in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
Recruiting
This study will look at how much CagriSema lowers blood sugar and body weight in people with type 2 diabetes. CagriSema is a new investigational medicine. Doctors cannot yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide. Doctors can prescribe tirzepatide in some countries. Participants will either receive CagriSema or tirzepatide. Which treatment the participant will receive is decided by chance. For each participant, the study will last for up to 1 year and 4... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/12/2025
Locations: Triad Research Institute, Norman, Oklahoma
Conditions: Diabetes Mellitus, Type 2
A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease
Recruiting
This is a Phase 2/3 study that comprises 5 substudies designed to evaluate the efficacy, safety, and tolerability of oral etrasimod as therapy in adult participants with moderately to severely active Crohn's disease (CD) who are refractory or intolerant to at least 1 of the current therapies for CD (ie, corticosteroids, immunosuppressants, or biologics). The overall duration of this study is up to 282 weeks, inclusive of the Screening Period, Treatment Period of up to 274 weeks (Induction, Exten... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/12/2025
Locations: Norman Endoscopy Center, Norman, Oklahoma +1 locations
Conditions: Crohn's Disease
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients
Recruiting
The purpose of the study is to assess the efficacy of durvalumab plus tremelimumab in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy in metastatic NSCLC patients with non-squamous histology who have mutations and/or co-mutations in STK11, KEAP1, or KRAS.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
02/03/2025
Locations: Research Site, Norman, Oklahoma
Conditions: Carcinoma, Non-Small-Cell Lung